Celiac disease (CD) is a T-cell-mediated chronic inflammatory disease characterized by autoimmune, immunological and environmental components, where genetic factors in addition to the main known risk factors (gliadin and human leukocyte antigen (HLA)-DQ haplotypes) are supposed to be involved. CD14 is a multifunctional receptor involved in the bacterial lipopolysaccharidesdependent signal transduction. The CD14 gene maps on the long arm of chromosome 5 (5q22-q32), a 'hotbed' region for CD; promoter polymorphisms are known to influence its expression. In this study we analyzed three CD14 promoter polymorphisms (c.-1359G4T, c.-1145A4G and c.-159C4T, ) in 938 CD Italian patients and 533 healthy controls, with known HLA-DQ haplotypes, with the aim of evaluating their possible association with the disease. The c.-1145A4G G and c.-159C4T T alleles (as well as the combination of the two alleles in the GT haplotype), were identified as susceptibility factors for CD development, being significantly more frequent in CD patients than in healthy controls. This association was also confirmed when the analysis was restricted to only those subjects characterized by HLA-DQ risk haplotypes. Our results indicate the involvement of CD14 gene polymorphisms in the susceptibility to CD.
INTRODUCTION
Celiac disease (CD), the most common food-sensitive enteropathy in humans, is a T-cell-mediated chronic inflammatory disease, characterized by autoimmune, immunological and environmental components 1, 2 that affects about 1% of the Caucasian population. 3 The disease consists in an immune response to ingested wheat gluten and related proteins that leads to inflammation, villous atrophy and crypt hyperplasia in the proximal part of the small intestine. 2, 4 Defect in antigen processing by epithelial cells, the presence of specific human leukocyte antigen (HLA)-DQ haplotypes together with gliadin's intrinsic properties, have been recognized as the main factors involved in CD pathogenesis. 4 CD presents a strong genetic susceptibility: around 90% of CD patients carry the HLA-DQ2 heterodimer (encoded by DQA1*05 and DQB1*02 alleles), while a smaller percent carry the HLA-DQ8 heterodimer (encoded by DQA1*03 and DQB1*0302 alleles). The HLA-DQ2 coding alleles can be encoded in cis on the DR3-DQ2 haplotype or in trans on the DR5-DQ7/DR7-DQ2 heterozygotes, while the HLA-DQ8 heterodimer is encoded in cis on the DR4-DQ8 haplotype. 5 Moreover, within individuals carrying DQ2 haplotype, two categories can be distinguished, the DQ2.5 (HLA DQA1*0501, DQB1*02 and DRB1*03) and the DQ2.2 (HLA DQA1*0201, DQB1*02 and DRB1*07). In spite of being both DQ2.5 and DQ2.2 able to recognize and present the gliadin peptides, only the DQ2.5 haplotypes confers a major risk to develop CD. In fact the HLA-DQ2.5 molecule can present a large variety of gluten peptides, while the HLA-DQ2.2 is able to present only a few. 6 Gliadin peptide presentation and T-cell activation are critical events in the pathogenesis of CD, as gluten peptides are not fully digested by gastric, intestinal and pancreatic enzymes in CD patients. 7 These peptides react with the tissue transglutaminase (tTG), the major autoantigen in CD, that deamidates to glutamic acid certain glutamine residues of gluten, producing a negative charge that favors the binding and presentation by HLA-DQ2 (DQ2.2/DQ2.5) and DQ8 molecules: this activates T cell and the production of T-helper 1 profile cytokines (especially interferongamma) and additional mediators that can activate other cell types, including cells of innate immunity, thus leading to tissue damage. 8 Nonetheless, the HLA-DQ loci have been estimated to account for less then 40% of CD heritability; 9 twin-based and family-based studies have shown a strong genetic component for CD development, with inherited risk also attributable to non-HLA genetic factors.
The CD14 molecule is a multifunctional receptor, mCD14, constitutively expressed on the surface of monocytes, macrophages and neutrophils, 11 while in the serum a monocyte-or liverderived soluble protein, sCD14, is predominant. 12 Both mCD14 and sCD14, are critical for the lipopolysaccharides-dependent signal transduction. 13 The CD14-lipopolysaccharides complex results in the activation of innate host defense mechanisms 14 by inducing a Th1 cytokine profile. 15 Moreover, CD14 is important for the recognition and clearance of apoptotic cells. 16 Changes in CD14 expression and serum sCD14 levels have been associated with a number of pathological conditions. [16] [17] [18] The CD14 gene maps on the long arm of chromosome 5 (5q22-q32), a 'hotbed' region for CD, and single-nucleotide polymorphisms (SNPs) in the promoter region of the gene are thought to regulate the CD14 gene expression. 19 With the aim of evaluating the possible association between CD14 and CD, we analyzed three CD14 promoter polymorphisms (namely c.-1359G4T, c.-1145A4G and c.-159C4T ) in 938 CD 1 Institute for Maternal and Child Health -IRCCS ''Burlo Garofolo'', Trieste, University of Trieste, Trieste, Italy and Italian patients and 533 healthy controls, with known HLA class II DQ genotype. The c.-1359G4T SNP had been previously associated with susceptibility to CD. 16 The c.-159C4T transition is located 159 bp upstream of the major transcription site, near to a SP1-binding site that has a major influence on the monocytespecific expression of CD14, and near a CCAAT-/enhancer-binding protein site that has an important role in the promoter activation of the CD14 gene during monocyte development. 17 Finally, the c.-1145A4G SNP is supposed to have a synergistic effect with the c.-159C4T SNP: both SNPs not only affect the transcriptional activity of the CD14 promoter, but also inhibit the expression of the CD14 gene. 18 
RESULTS
Within the 938 CD patients analyzed, 18% were DQ2.2, 63% DQ2.5 and 19% DQ8 positive. The frequency of celiac patients without the entire HLA risk heterodimer has been estimated at 6/1000: 20 in our study we did not find any celiac patient without the HLA heterodimer associated with susceptibility to develop the disease. Twenty percent of controls were DQ2.2, 49% DQ2.5 and 13% DQ8 positive, and the remaining 18% were characterized by HLA-DQ genotypes different from DQ2.2, DQ2.5 or DQ8 and not associated with CD. The female/male ratio was 1.69 in CD patients, and 1.45 in controls. Patients and controls characteristics are summarized in Supplementary Table S1 . Allelic and genotype frequencies for the c.-1359G4T, c.-1145A4G and c.-159C4T SNPs are reported in Tables 1, 2 and 3, respectively. In order to investigate the possible association between CD14 polymorphisms and CD, we firstly compared the three SNPs frequency distributions between all CD patients and the total of healthy controls (regardless of their HLA-DQ haplotypes).
Allelic and genotype frequencies for the c.-1359G4T polymorphism were in Hardy-Weinberg equilibrium in healthy controls but not in CD patients (Table 1 ). No differences in the frequency distribution were observed when comparing CD patients and controls. Allele and genotype frequencies of the c.-1145A4G polymorphism were in Hardy-Weinberg equilibrium in both CD patients and healthy controls ( Table 2 ). The c.-1145A4G G allele and GG genotype were significantly more frequent in the CD patients with respect to controls (P ¼ 0.006), and both associated with an increased risk for the disease development (odds ratio (OR) 1.24 and 1.52, respectively).
The c.-159C4T genotypes distribution was in Hardy-Weinberg equilibrium in controls, but not in the CD patients ( Table 3 ). The c.-159C4T T allele and CT genotype were significantly more frequent in CD patients than controls (P ¼ 0.0002 and P ¼ 7.22e-05), indicating an association with an increased risk of CD (OR 1.35 and 1.57, respectively). Also the TT genotype was more frequent in CD patients than controls, but the P-value for this comparison (P ¼ 0.018) was just slightly above the significance threshold fixed (Pr0.016). Nonetheless, the results are indicative of a recessive effect of the C allele: the c.-159C4T C allele is associated with a protection towards CD when in homozygosis. (CC vs TC þ TT, P-value ¼ 2.862e-05; OR 0.63; 95% confidence interval (CI): 0.50-0.79).
With the aim of investigating the presence of linkage disequilibrium (LD) and a possible combined effect of the three polymorphisms in the susceptibility for CD disease, we then performed a haplotype analysis, using Arlequin software (version 3.1). 21 The strongest LD was found between the c.-1145A4G and c.-159C4T SNPs (Po0.0001, D 0 40.95), and, although to a lesser extent, also the c.-1359G4T SNP was in LD with these SNPs (Po0.000, D 0 40.70), in both patients and controls. The GGT haplotype (the only haplotype presenting the c.-159C4T T allele) was more frequent in CD patients than controls, and associated with an increased risk of CD, when compared with the sum of other haplotypes presenting the c.-159C4T C allele (GAC, TAC and GGC; OR 1.60; 95% CI: 1.28-2.02; P-value ¼ 2.39e-05, data not shown.). As for the c.-1359G4T no association with CD was evidenced at the allelic or genotype level, while we found an association for the c.-159C4T and c.-1145A4G SNPs, and considering that c.-159C4T T and c.-1145A4G A alleles are in strong LD and thought to have a synergic effect, 18 we decided to restrict the haplotype analysis only to these two polymorphisms. The c.-1145A4G and c.-159C4T SNPs combined into three major haplotypes ( Table 4 ). The GT haplotype was significantly more frequent in CD patients than controls, and associated with an increased risk of CD (OR 1.37, 95% CI: 1.15-1.64, P-value ¼ 0.0003).
All CD patients included in the study (and 82% of controls) were characterized by HLA-DQ haplotypes associated with high risk for CD (DQ2.2, DQ2.5 or DQ8, globally indicated as R), while 18% of controls were characterized by HLA-DQ haplotypes different from DQ2.2, DQ2.5 or DQ8 and not associated with CD (indicated as NR).
As the HLA-DQ is the major susceptibility genetic locus known to be associated with CD, we wanted to exclude that the different HLA-DQ distribution between patients and controls may have biased the CD14 association results, and disclose whether this association was dependent on, or restricted to, specific HLA-DQ haplotypes. For this reasons we compared the CD14 SNPs frequencies between patients and controls characterized by the same HLA-DQ haplotypes. In particular, we performed a first comparison between all patients and all controls that presented HLA-DQ haplotypes associated with CD risk (R-CD patients vs R-controls). Then, we compared patients and controls within each HLA-DQ subgroup (that is, DQ2.2 patients vs DQ2.2 controls and so on). For the c.-1359G4T polymorphism no differences in frequency distribution were observed when comparing any CD patients and controls subgroup ( Table 1, and Supplementary Table  S2 ). The c.-1145A4G G allele was significantly more frequent in R-CD patients than R-controls (P ¼ 0.003), as well as the GG genotype (P ¼ 0.004) ( Table 2 ). Thus, both the presence of G allele and GG genotype correlates with an increased risk of developing CD (OR 1.28 and 1.60, respectively) in subjects presenting HLA-DQ risk haplotypes. When we considered each subgroup of HLA-DQ individuals, we found that the association was confirmed comparing DQ2.5 controls with DQ2.5 patients; conversely, when comparing DQ2.2 controls and DQ2.2 CD patients, as well as DQ8 controls with DQ8 CD patients, no differences were evidenced (Supplementary Table S2) . Similarly to what observed in the total of controls and patients, the c.-159C4T T allele and CT genotypes were significantly more frequent in R-CD patients than R-controls (P ¼ 8.81e-05 and P ¼ 2.26e-05) (Table 3) . Moreover, in this comparison, also the differences for the TT genotypes reached the statistical significance (P ¼ 0.012). These data confirm, in subjects characterized by HLA-DQ risk haplotypes, the role of the c.-159C4T CC genotype in conferring protection towards CD development (OR 0.59; 95% CI: 0.46-0.75, P-value ¼ 7.60e-06).
The association was evident also in DQ2.2 and DQ2.5 subgroups, but not in DQ8 (Supplementary Table S2 ).
When analyzing CD14 haplotypes stratified according to HLA-DQ (Table 4) , the GT haplotype was significantly more frequent also in R-CD patients than R-controls, showing an association with an increased risk of CD (OR 1.44, 95% CI: 1.19-1.74, P ¼ 0.0001). The association was evident also in DQ2.5 subgroup, but not in DQ2.2 and DQ8 (Supplementary Table S2 ).
DISCUSSION
CD is a permanent gluten sensitive enteropathy with an established genetic predisposition. A well-known genetic factor involved in CD susceptibility, the CELIAC1, lies in the HLA class II region on chromosome 6p21 22 and contains HLA-DQ2 (both DQ2.5 and DQ2.2) and HLA-DQ8 CD14 polymorphisms and celiac disease E Catamo et al haplotypes. As the HLA-DQ loci have been estimated to account for o40% of CD heritability, 9 other regions of interest have been also investigated: a linkage at 5q31-33 region (CELIAC2), was firstly identified in an Italian genome scan 23 and thereafter in subsequent linkage studies in other populations. [24] [25] [26] [27] [28] In addition, a pooled analysis, using raw data from four independent genome scans, further confirmed linkage to this region. 29 Apart from the HLA region, 5q31-33 was the only region in this study that reached genome-wide level of significance as defined by Lander and Kruglyak. 30 To identify the CD susceptibility gene(s) located at 5q31-33, Amundsen et al. 31 performed an extensive SNP association screening of the 16 Mb region, which defines the 95% CI (position 131.895.324-148.053.211 bp) of the linkage peak previously found in the Swedish/Norwegian CD cohort. 27 Unfortunately, the authors were unable to identify an association signal of any of the markers that alone could explain the linkage signal observed in the same patient cohort, probably because of collective effects of multiple risk genes within the region, incomplete genetic coverage or effects related to copy number variation.
The chromosome 5q encodes several genes with demonstrated or potential involvement in autoimmune and/or inflammatory disease, such as CD14 gene, encoding for the CD14 molecule. The involvement of CD14 in bacterial recognition 13, 15 and in the modulation of the inflammatory response [32] [33] [34] as well as its genetic location in a ''hotbed'' region for susceptibility to CD, lead us to hypothesize a possible role for CD14 gene in the development of the disease. We therefore analyzed three CD14 polymorphisms, -1359G4T, -1145A4G and -159C4T, located in the promoter region of the gene, supposed to be involved in the regulation of CD14 gene expression. 19 Boniotto et al., 16 in a study performed on Italian celiac patients, had previously reported an increased frequency of the c.-1359G4T TT genotype in HLA-DQ2.2 patients when compared with the controls. In our study, both allele and genotype frequencies of this SNPs were substantially comparable between CD patients and controls, as well as between patients and controls stratified according to their HLA-DQ haplotypes. This one is not the only discrepancy between our study and the Boniotto et al. 16 one. In fact, while Boniotto et al. 16 lacked to find any association between CD14 c.-159C4T SNP and CD, our results indicate the c.-159C4T CC genotype as associated with a protective effect toward the development of CD, both in the overall population, as well as in subjects characterized by genetic HLA predisposition for the disease (OR ¼ 0.59, 95% CI: 0.47-0.75), especially DQ2.2 and DQ2.5.
The differences between the study of Boniotto et al. 16 and ours could be possibly because of the fact that controls in the study Boniotto et al. 16 were not stratified for HLA haplotype, and the lower number of DQ2.2 patients (37 individuals, vs the 127 in our study) analyzed by Boniotto et al. 16 could also account for this discrepancy. It should also be noticed that the genotype distribution of both c.-1359G4T and c.-159C4T SNPs in the healthy controls were significantly different between the two studies (P ¼ 0.018 and P ¼ 1.329e-07). This may implicate that, despite being two Italian populations, some ethnic differences may exist between the two groups possibly explaining the differences encountered.
Evidence indicates that the c.-159C4T T allele is associated with an increase of CD14 expression: Hubacek et al. 35 reported a higher density of CD14 receptor measured by flow cytometry in subjects characterized by c.-159C4T TT genotype; Baldini et al. 34 observed that TT homozygotes had significantly higher sCD14 levels than the carriers of both CC and CT genotypes. LeVan et al. 36 also showed that the T allele confers higher transcriptional activity in a monocyte cell line by preferential binding of the activating Sp1 and Sp2 transcription factors, using EMSAs and in reporter gene assay. Mertens et al. 37 confirmed in vivo the findings of LeVan et al. 36 suggesting that the T allele confers stronger transcription initiation than the C allele and that transcription factor binding might stabilize RNA polymerase II binding. The increased CD14 expression, in presence of c.-159C4T T allele and in particular of the TT genotype, may lead to an increased activation of the TLR4 receptor, thereby eliciting a stronger reaction to bacterial infection. 38 The consequent inflammation in the jejunal mucosa may disrupt the intestinal permeability barrier, leading to an increased gluten load in the lamina propria, where most of the gluten-reactive lymphocytes are situated, thus explaining the increased susceptibility to CD found in individuals with the c.-159C4T TT genotype 25 and the protective effect of the CC genotype we reported.
In our study, also the -1145A4G polymorphism showed a significantly different frequency distribution when comparing CD patients and controls, being the c.-1145A4G G allele and GG genotype associated with an increased risk for the disease development. Gu et al. 18 suggested that c.-159C4T C allele not only affects the transcriptional activity of the CD14 promoter, but also inhibits the expression of CD14, showing a synergistic effect with the c.-1145 A allele. Our haplotypes analysis, in agreement with the work of Gu et al., 18 showed strong LD between c.-159C4T and c.-1145A4G polymorphisms, with the AC haplotype more frequent in the controls with respect to CD patients and the GT haplotype (the only one presenting the c.-159C4T T allele) significantly more frequent in CD patients than controls.
Both differences in frequency distribution encountered for the c.-159C4T and c.-1145A4G polymorphisms, were evident between the total of patients and controls, as well as comparing patients and controls stratified for HLA-DQ risk haplotypes, with the exception of the DQ2.2 (for the c.-1145A4G) and the DQ8 groups, for both SNPs. None of the associations reported in fact could be evidenced when comparing the DQ8 patients with the group of DQ8 healthy controls. This fact could be because of the reduced number of healthy controls characterized by this HLA-DQ haplotype. No significant differences were evidenced for the CD14 polymorphisms within patients (comparing DQ2.2, DQ2.5 and DQ8 individuals) as well as within controls, with the only exception of the c.-159C4T CT genotype that was significantly more frequent in DQ2.2 than DQ8 patients (P ¼ 0.001). Although the different CD14 SNPs frequencies in the different DQ-groups of patients are probably random effects due to a small sample size, we can not completely exclude that the involvement of CD14 in CD susceptibility is restricted to HLA-DQ-specific genotypes, although to our knowledge there are no known evidence of differences in CD14 function between HLA Class II different groups or known association between CD14 and HLA. Nonetheless, Fernandes et al. 39 have found that type I diabetes patients presenting the HLA-DQB1*0201 allele exhibited lower percentage of CD14 þ cells bearing HLA-DQ molecules, when compared with T1D patients without the HLA-DQB1*0201 allele. The significance of this finding, and if this happens also in CD, remains to be demonstrated.
All this considered, our results suggest an involvement of CD14 gene in the susceptibility to CD, being the c.-159C4T T and c.-1145A4G G alleles associated with an increased risk of CD development. This association was found in the global population analyzed, as well as when the analysis was restricted to subjects characterized by genetic HLA predisposition for the disease, especially DQ2.2 and DQ2.5, but not DQ8. Replica studies on other ethnic groups are undoubtedly encouraged in order to disclose the possible role of CD14 gene/molecule in CD and the eventual association with HLA-DQ.
MATERIALS AND METHODS

Subject and controls
We enrolled for this study 938 CD Italian patients (European-Caucasian, mean age 17.08 ± 15.41 years, range 2-70) stratified for the presence of the following HLA class II (DQ) haplotypes: 169 patients DQ2.2 (DQA1*0201/ CD14 polymorphisms and celiac disease E Catamo et al DQB1*02/DRB1*07), 593 patients DQ2.5 (DQA1*05/DQB1*02/DRB1*03) and 176 patients DQ8 (DQA1*03/DQB1*0302/DRB1*04). Patients' demographic characteristics are reported in Supplementary Table S1 . All patients were recruited from a historical cohort at the Gastroenterology Service of IRCCS Burlo Garofolo (Trieste, Italy) from July 2000 to December 2009. CD diagnosis was made according to the European Society for Pediatric Gastroenterology, Hepatology and Nutrition guidelines: 40 after the evaluation of clinical symptoms, an anti-tTG serological test was performed (with the ELISA Eu-tTG kit; Eurospital, Trieste, Italy), and EMA antibodies were subsequently screened (with the Antiendomysium Kit; Eurospital) for results confirmation when ambiguous serological results were achieved. Molecular HLA typing was used to confirm the serological diagnosis and to exclude CD in doubtful cases. An intestinal biopsy was also performed for all CD patients and presence of histological infiltrative lesion (Marsh 1) was considered as predictive of CD. In symptomatic CD patients with normal intestinal mucosa and positive serology, after HLA typing, immunohistochemical analysis was performed to determine the number of CD3-positive intraepithelial lymphocytes, using CD4, CD8 and CD25 as population markers. 41, 42 All patients, following CD diagnosis, started a gluten-free diet, whose effects were measured using tTG serology (Eu-tTg kit; Eurospital). Values below 7 AU (absorbance units) were considered as negative; values comprised between 7 and 10 AU were considered borderline and required EMA analysis; values above 10 AU were considered positive. EMA and HLA typing were performed in individuals with the borderline values (8.2 ± 1.3 AU) to confirm CD diagnosis. The mean serum anti-tTG value was 39.5 ± 5.3 AU (range 13-174) in CD patients; the mean serum anti-tTG value was 1.8±0.3 AU (range 0.1-5.3) in the healthy controls. After glutenfree diet in all CD patients tTG autoantibodies declined and were always under the cutoff value of 7 AU.
As healthy controls we enrolled 533 European-Caucasian individuals (mean age 36.25 ± 12.69 years, range 1-70) stratified for the presence of the following HLA class II haplotypes: 108 DQ2.2, 260 DQ2.5, 68 DQ8 and 97 no-DQ2.2/no-DQ2.5/no-DQ8 (NR). Controls demographic characteristics are reported in Supplementary Table S1 .
All subjects were not on gluten-free diet and had no clinical signs related to the disease and no familiar history of CD. CD was excluded by testing the subjects for the presence of anti-tTG antibodies. The study was approved by the local ethical committee (Burlo Garofolo protocol no. CE/V-71).
DNA extraction and HLA genotyping Genomic DNAs were extracted from peripheral whole blood for all patients and controls using the Wizard Genomic Purification kit (Promega, Madison, WI, USA) following the manufacturer's indications. Because of the prolonged period of patients' recruitment, we used different methods for HLA class II molecular typing. Before the routine introduction of the Eu-Gen Risk kit a validation on 500 CD samples with known HLA genotype was performed as recommended by our laboratory guidelines. The validation was 100% successful with no falsepositive or -negative HLA genotyping results, so the new kit was introduced in the routine analysis and substituted the Dynal-All Set kits. Internal quality controls were performed according to the guidelines of the Italian Society of Human Genetics (SIGU-Società Italiana di Genetica Umana).
HLA genotyping in the healthy controls was performed using a Tag-SNPs approach as reported by Monsuur et al. 43 and Koskinen et al. 44 The choice of the Tag-SNPs method for HLA genotyping was based on its low cost and high throughput; before its introduction as a genotyping method, the TagSNPs method was validated with HLA-known samples previously genotyped with Dynal/Eu-Gen Risk kits. 45 CD14 genotyping CD14 c.-159C4T (rs2569190), and c.-1145A4G (rs2569191) polymorphisms were detected using, respectively, C_16043997_10 and C_16043996_20 fluorogenic TaqMan SNP Genotyping Assay (Applied Biosystem, Forster City, CA, USA) and 7900HT Real-Time PCR System (Applied Biosystem).
c.-1359G4T polymorphism (rs3138078) was detected by PCR-RFLP following the protocol of Boniotto et al. 16 PCR products were digested for 2 h at 37 1C with the endonuclease FokI (New England Biolabs, Beverly, MA, USA) and subsequently separated on a 2% agarose gel. The G allele showed one fragment of 303 bp, while the T allele showed two fragments of 215 and 88 bp.
Statistical analyses
Allele and genotype frequencies were calculated by direct gene counting. Statistical significance of difference in allele and genotype frequencies was calculated by Fisher's exact test. The OR and 95% CI were also computed. The open-source R package (www.r-project.org) was used for all statistical analyses. When calculating and presenting P-values and OR in tables, the alleles and corresponding homozygous genotypes with major frequency in the control subjects have been selected as reference (OR ¼ 1) and the other ORs have been presented relative to that reference (Fisher's exact test, 2 Â 2 contingency tables, degrees of freedom ¼ 1). Bonferroni's correction was performed and thus only Pr0.016 were considered statistically significant. Haplotypes and the eventual presence of LD between CD14 polymorphisms were evaluated by using the free available online software Arlequin 3.11 (http://cmpg.unibe.ch/software/arlequin3). 21 
